GlassScriptPhysician profile
Claudia C Gore
NPI 1700429164
$6,557.53
in general payments reported to CMS, 2019-2025
20 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $2,380 · 2024: $2,175 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,306 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,306.32 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,011.64 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $670.32 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $596.34 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $557.39 | 2022-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $526.99 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $506.32 | 2022-2025 | Trintellix |
| Corium, LLC | $486.23 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $464.10 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $453.12 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $409.52 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $248.57 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $161.36 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $111.72 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $93.54 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $90.64 | 2023-2024 | Adzenys Xr-Odt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $63.15 | 2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $53.14 | 2022-2025 | Aplenzin |
| Almatica Pharma LLC | $23.91 | 2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $14.89 | 2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.